Rapamycin

Rapamycin, marketed as sirolimus, is a naturally occurring macrocyclic lactone that inhibits the mechanistic target of rapamycin (mTOR) and has both immune-suppressing and cell-growth-suppressing effects ^[1][3]. It was isolated in the 1970s from Streptomyces hygroscopicus, a bacterium recovered from a soil sample on Easter Island, known to its inhabitants as Rapa Nui, from which the compound takes its name ^[1]. First described as an antifungal agent, it was later found to have powerful effects on the immune system and on cell growth ^[1].

The compound was approved at the end of the 1990s to help prevent rejection of transplanted organs, particularly kidneys, where it offers the advantage of being less toxic to the kidney than the calcineurin inhibitors. It is additionally used to coat coronary stents so as to keep arteries from renarrowing after they are opened, and to treat several rare disorders, including the lung disease lymphangioleiomyomatosis and certain abnormal vascular growths. In these settings its ability to restrain cell proliferation and immune activity is central to its usefulness.

Beyond these approved uses, rapamycin has become one of the most intensively studied molecules in the biology of aging. Suppressing the mTOR pathway lengthens lifespan in yeast, roundworms, and fruit flies, and in 2009 a landmark experiment showed that rapamycin extended both median and maximum lifespan in genetically varied mice even when treatment was begun late in life ^[2]. Later research showed that prolonged dosing can worsen glucose tolerance by disrupting a second protein assembly called mTORC2, though the same study indicated that reduced signaling through the first complex, mTORC1, could extend lifespan independently of these metabolic changes ^[3]. Interest in the drug's potential to influence age-related disease continues, while its immune-suppressing and metabolic effects temper enthusiasm for broad use ^[3].

Sirolimus is a prescription-only medicine supplied as an oral solution and tablets, with related formulations used for specific indications. Its discovery from a single soil sample illustrates how the screening of natural products has yielded compounds of lasting scientific and medical importance ^[1].

As an immunosuppressant it can raise infection risk, impair wound healing, and cause mouth sores, and continuous high dosing can worsen blood lipids and blood sugar. Intermittent low-dose protocols used for longevity aim to reduce these risks, but long-term safety for that use is not established. It interacts with many drugs and should only be used under medical supervision.

Rapamycin is metabolized primarily by cytochrome P450 3A (CYP3A), and its blood levels change substantially when combined with other drugs that inhibit or induce this enzyme. CYP3A inhibitors increase rapamycin exposure significantly; when combined with voriconazole, used for fungal infections, rapamycin levels can rise, and patients require dose reductions and close monitoring of blood concentrations to prevent toxicity ^[19].

Conversely, CYP3A enzyme inducers like rifampin and certain anticonvulsants decrease rapamycin exposure substantially; in one study, rifampin reduced the active metabolite of temsirolimus (a rapamycin derivative) by 56 to 67 percent, necessitating higher doses to maintain therapeutic levels ^[20]. This is a pharmacokinetic interaction where one drug changes the blood concentration of the other through enzyme effects. Understudied pairings include rapamycin with most oral antibiotics, antihistamines, and non-enzyme-modulating antifungal agents; the interaction risk with most antivirals and cardiovascular drugs remains unclear.

Checking a whole stack? Run it through interactions + stacks.

Rapamycin, also known as sirolimus, was isolated in the early 1970s from Streptomyces hygroscopicus, a soil bacterium recovered from Easter Island, known to its inhabitants as Rapa Nui, during a bioprospecting effort by researchers at the pharmaceutical company Ayerst. The compound is closely associated with the scientist Suren Sehgal, who characterized and championed it after it was first noticed for antifungal activity.

Attention soon shifted to its powerful immunosuppressant and antiproliferative properties, and in 1999 the United States Food and Drug Administration approved it as Rapamune to prevent rejection in kidney transplantation; it was later used to coat coronary stents and to treat rare conditions such as lymphangioleiomyomatosis. The identification of its molecular target, the mTOR pathway, opened an entire field of research into cellular growth and metabolism. A pivotal 2009 study showing that rapamycin extended the lifespan of mice even when begun late in life transformed it into one of the most studied compounds in the biology of aging.

Rapamycin occupies a singular place in modern biomedicine, respected both as an established transplant and stent medicine and as arguably the most compelling pharmacological candidate in the science of longevity. It is frequently described as the only drug shown to extend lifespan in every model organism in which it has been rigorously tested, an effect that is notably dose- and sex-dependent.

Its reputation in aging research rests on a robust and growing literature: reviews highlight strong evidence for benefits on cardiac function, the nervous system, cellular senescence, and immune aging in mice, and short courses of low-dose mTOR inhibition have been reported to rejuvenate aspects of the aging immune system in older adults. Researchers are appropriately measured about translating this promise; prolonged high-dose exposure can impair insulin action and immune defense through effects on a second complex, mTORC2. Even so, its combination of a defined mechanism and reproducible lifespan effects gives rapamycin a uniquely optimistic standing in geroscience.